Message #1 From:
Jason Date: June 4, 2007 08:23:18 AM
ACHN, Achillion Announces the Resignation of John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN Stock Forum) today announced that John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer, has resigned to accept a senior clinical development position at GlaxoSmithKline. His resignation will become effective on May 29, 2007. Milind Deshpande, Ph.D., Senior Vice President and Chief Scientific Officer, will assume leadership of Achillion's clinical development activities in addition to his current drug discovery responsibilities.
'John has played a significant role in building a strong clinical development organization as Achillion moves toward pivotal trials for its lead HIV candidate, elvucitabine. We wish John all the best with his new endeavor and thank him for his years of service to Achillion,' said Michael Kishbauch, President and Chief Executive Officer of Achillion. 'Milind's prior development experience will enable him to maintain the momentum of our clinical programs as we conduct our search for a new chief medical officer.'
Dr. Deshpande joined Achillion in September 2001 as Vice President of Chemistry, was named head of drug discovery in April 2002, and Vice President of Drug Discovery in December 2002. Prior to Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb from 1991 to 2001. From 1988 to 1991, he held a faculty position at Boston University Medical School.
About ACHN Achillion
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- HIV, hepatitis and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at http://www.achillion.com or call Achillion at 1-203-624-7000.
